AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:50:59 21/01/2025 GMT			5-day change	1st Jan Change
10,899.00 ^GBX	+0.97%		+2.46%	+4.05%

07:05am	ASTRAZENECA : Goldman Sachs gives a Buy rating	ZD
06:06am	Trinasolar Partners with Smart Commercial Solar to Deliver Advanced Solar Panel Installation for AstraZeneca's New Major Rooftop Car Park At Its Macquarie Park Manufacturing Complex	CI

ASTRAZENECA : Goldman Sachs gives a Buy rating

December 05, 2024 at 12:08 pm

In a research note, Goldman Sachs analyst Rajan Sharma has maintained his recommendation on the stock with a Buy rating. The target price remains set at GBX 15955.

Latest news about AstraZeneca PLC

ASTRAZENECA : Goldman Sachs gives a Buy rating	07:05am	ZD
Trinasolar Partners with Smart Commercial Solar to Deliver Advanced Solar Panel Installation for AstraZeneca's New Major Rooftop Car Park At Its Macquarie Park Manufacturing Complex	06:06am	CI
Jefferies raises Spirax; Peel Hunt cuts Grainger	01-20	AN
AstraZeneca: first approval for Dato-DXd in the USA	01-20	CF
FTSE 100 : Markets in holding pattern	01-20
Stocks down; BT's Openreach unveils network expansion	01-20	AN
ASTRAZENECA : Gets a Neutral rating from Jefferies	01-20	ZD
AstraZeneca, Daiichi Sankyo Win US FDA Nod for Breast Cancer Treatment Datroway	01-19	MT
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway	01-17	DJ
DATROWAY® Approves in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	01-17	CI
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	01-17	MT
USA: 15 new drugs on the negotiation list	01-17	CF
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	01-17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	01-17	MT
AstraZeneca overhauls management of its China division, FT reports	01-17	RE
Astrazeneca Says Mantle Cell Lymphoma Combination Treatment Receives FDA Approval	01-17	MT
FTSE 100 : Merger murmurs and Chinese data boost stocks	01-17
AstraZeneca's Calquence gets US approval for mantle cell lymphoma	01-17	AN
AstraZeneca: Calquence approved for LCM by the FDA	01-17	CF
Stocks called up but UK retail sales miss forecasts	01-17	AN
AstraZeneca Gets US FDA Nod for Lymphocytic Leukemia Treatment Calquence	01-17	MT
Astrazeneca Announces Approval of Calquence (Acalabrutinib) in Combination with Bendamustine and Rituximab in the US for the Treatment of Adult Patients	01-17	CI
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca	01-15	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	01-15	ZD
Stockholm Bullets - Millicom rises on new dividend policy	01-15	FW

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

06/02/2025 - Q4 2024 Earnings Release

More about the company